{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:32Z","timestamp":1783486172788,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11307-024-01945-7","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T16:19:05Z","timestamp":1724429945000},"page":"847-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Ephraim E.","family":"Parent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna J.","family":"Gleba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad J.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6278-1258","authenticated-orcid":false,"given":"Hancheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"1","key":"1945_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Gosnell JE, Roman SA (2020) Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 16(1):17\u201329","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"1945_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41574-020-0398-9","volume":"16","author":"JD French","year":"2020","unstructured":"French JD (2020) Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies. Nat Rev Endocrinol 16(11):629\u2013641","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1945_CR3","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1530\/ERC-15-0555","volume":"23","author":"D Viola","year":"2016","unstructured":"Viola D et al (2016) Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 23(4):R185-205","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1945_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","volume":"135","author":"T Kogai","year":"2012","unstructured":"Kogai T, Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 135(3):355\u2013370","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1945_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0300-9084(99)80078-9","volume":"81","author":"K Suzuki","year":"1999","unstructured":"Suzuki K et al (1999) Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. Biochimie 81(4):329\u2013340","journal-title":"Biochimie"},{"issue":"6","key":"1945_CR6","doi-asserted-by":"publisher","first-page":"R191","DOI":"10.1530\/ERC-17-0010","volume":"24","author":"CW Rowe","year":"2017","unstructured":"Rowe CW et al (2017) Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer 24(6):R191\u2013R202","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1945_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jcem-51-4-915","volume":"51","author":"P Carayon","year":"1980","unstructured":"Carayon P et al (1980) Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 51(4):915\u2013920","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1945_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/en.2003-1217","volume":"145","author":"SP Singh","year":"2004","unstructured":"Singh SP et al (2004) Upon thyrotropin binding the thyrotropin receptor is internalized and localized to endosome. Endocrinology 145(2):1003\u20131010","journal-title":"Endocrinology"},{"issue":"6","key":"1945_CR9","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2214\/AJR.13.11673","volume":"202","author":"C Marcus","year":"2014","unstructured":"Marcus C et al (2014) PET\/CT in the management of thyroid cancers. AJR Am J Roentgenol 202(6):1316\u20131329","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1945_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2967\/jnumed.115.168138","volume":"57","author":"JW Kist","year":"2016","unstructured":"Kist JW et al (2016) 124I PET\/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer: results of a multicenter diagnostic cohort study (THYROPET). J Nucl Med 57(5):701\u2013707","journal-title":"J Nucl Med"},{"issue":"3","key":"1945_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/RLU.0000000000001977","volume":"43","author":"S Samnick","year":"2018","unstructured":"Samnick S et al (2018) Initial clinical investigation of [18F]Tetrafluoroborate PET\/CT in comparison to [124I]Iodine PET\/CT for imaging thyroid cancer. Clin Nucl Med 43(3):162\u2013167","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1945_CR12","first-page":"57","volume":"19","author":"F Corsetti","year":"2004","unstructured":"Corsetti F et al (2004) Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother Radiopharm 19(1):57\u201363","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"1945_CR13","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1210\/jc.2012-3080","volume":"97","author":"MC Gershengorn","year":"2012","unstructured":"Gershengorn MC, Neumann S (2012) Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 97(12):4287\u20134292","journal-title":"J Clin Endocrinol Metab"},{"key":"1945_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/B978-0-12-381296-4.00022-1","volume":"485","author":"J Sanders","year":"2010","unstructured":"Sanders J et al (2010) TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods Enzymol 485:393\u2013420","journal-title":"Methods Enzymol"},{"issue":"8","key":"1945_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1089\/thy.2013.0429","volume":"24","author":"F Galli","year":"2014","unstructured":"Galli F et al (2014) Tc-99m-Labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid 24(8):1297\u20131308","journal-title":"Thyroid"},{"issue":"9","key":"1945_CR16","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/jcm10091878","volume":"10","author":"F Galli","year":"2021","unstructured":"Galli F et al (2021) In vivo imaging of thyroid cancer with Tc-99m-TR1401 and Tc-99m-TR1402: a comparison study in dogs. J Clin Med 10(9):1878","journal-title":"J Clin Med"},{"issue":"1","key":"1945_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.surg.2023.05.045","volume":"175","author":"GR Gimblet","year":"2023","unstructured":"Gimblet GR et al (2023) Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer. Surgery 175(1):199\u2013206. https:\/\/doi.org\/10.1016\/j.surg.2023.05.045","journal-title":"Surgery"},{"issue":"6","key":"1945_CR18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.14681","volume":"96","author":"J Furmaniak","year":"2022","unstructured":"Furmaniak J et al (2022) TSH receptor specific monoclonal autoantibody K1\u201370(TM) targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf) 96(6):878\u2013887","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1945_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13317-019-0121-9","volume":"10","author":"J Furmaniak","year":"2019","unstructured":"Furmaniak J et al (2019) Preclinical studies on the toxicology, pharmacokinetics and safety of K1\u201370(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity. Auto Immun Highlights 10(1):11","journal-title":"Auto Immun Highlights"},{"issue":"31","key":"1945_CR20","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","volume":"30","author":"SM Knowles","year":"2012","unstructured":"Knowles SM, Wu AM (2012) Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30(31):3884\u20133892","journal-title":"J Clin Oncol"},{"issue":"3","key":"1945_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","volume":"73","author":"M Evans","year":"2010","unstructured":"Evans M et al (2010) Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol 73(3):404\u2013412","journal-title":"Clin Endocrinol"},{"key":"1945_CR22","doi-asserted-by":"publisher","unstructured":"N\u00fa\u00f1ez\u00a0Miguel R et al (2022) Structure of full-length TSH receptor in complex with antibody K1\u201370. J Mol Endocrinol 70(1). https:\/\/doi.org\/10.1530\/JME-22-0120","DOI":"10.1530\/JME-22-0120"},{"issue":"7","key":"1945_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.0c00087","volume":"32","author":"SK Sharma","year":"2021","unstructured":"Sharma SK et al (2021) A systematic evaluation of antibody modification and (89)Zr-radiolabeling for optimized immuno-PET. Bioconjug Chem 32(7):1177\u20131191","journal-title":"Bioconjug Chem"},{"issue":"4","key":"1945_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nprot.2010.13","volume":"5","author":"MJ Vosjan","year":"2010","unstructured":"Vosjan MJ et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5(4):739\u2013743","journal-title":"Nat Protoc"},{"issue":"9","key":"1945_CR25","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1210\/jc.2017-01845","volume":"103","author":"LA Marlow","year":"2018","unstructured":"Marlow LA et al (2018) Methodology, criteria, and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts. J Clin Endocrinol Metab 103(9):3169\u20133182","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1945_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/BF02067383","volume":"16","author":"MJ Demeure","year":"1992","unstructured":"Demeure MJ et al (1992) Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases. World J Surg 16(4):770\u2013776","journal-title":"World J Surg"},{"issue":"1","key":"1945_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/0003-2697(84)90517-7","volume":"142","author":"CF Meares","year":"1984","unstructured":"Meares CF et al (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142(1):68\u201378","journal-title":"Anal Biochem"},{"issue":"2","key":"1945_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1152\/physrev.00031.2001","volume":"82","author":"MW Szkudlinski","year":"2002","unstructured":"Szkudlinski MW et al (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82(2):473\u2013502","journal-title":"Physiol Rev"},{"issue":"10","key":"1945_CR29","first-page":"1597","volume":"31","author":"M Ryder","year":"2021","unstructured":"Ryder M et al (2021) Blocking the thyrotropin receptor with K1\u201370 in a patient with follicular thyroid cancer, Graves\u2019 disease, and Graves\u2019 ophthalmopathy. Thyroid 31(10):1597\u20131602","journal-title":"Thyroid"},{"issue":"10","key":"1945_CR30","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1021\/acs.bioconjchem.8b00632","volume":"29","author":"A Moroz","year":"2018","unstructured":"Moroz A et al (2018) A preclinical assessment of (89)Zr-atezolizumab identifies a requirement for carrier added formulations not observed with (89)Zr-C4. Bioconjug Chem 29(10):3476\u20133482","journal-title":"Bioconjug Chem"},{"issue":"19","key":"1945_CR31","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-21-0453","volume":"27","author":"L Kist de Ruijter","year":"2021","unstructured":"Kist de Ruijter L et al (2021) First-in-human study of the biodistribution and pharmacokinetics of 89Zr-CX-072, a novel immunopet tracer based on an anti-PD-L1 probody. Clin Cancer Res 27(19):5325\u20135333","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1945_CR32","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.4049\/jimmunol.164.12.6158","volume":"164","author":"EU Bagriacik","year":"2000","unstructured":"Bagriacik EU, Klein JR (2000) The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RBhigh lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol 164(12):6158\u20136165","journal-title":"J Immunol"},{"issue":"2","key":"1945_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","volume":"115","author":"E Abe","year":"2003","unstructured":"Abe E et al (2003) TSH is a negative regulator of skeletal remodeling. Cell 115(2):151\u2013162","journal-title":"Cell"},{"issue":"10","key":"1945_CR34","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","volume":"25","author":"I Landa","year":"2019","unstructured":"Landa I et al (2019) Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res 25(10):3141\u20133151","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1945_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1517\/14728222.2015.1018181","volume":"19","author":"TF Davies","year":"2015","unstructured":"Davies TF, Latif R (2015) Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies. Expert Opin Ther Targets 19(6):835\u2013847","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"1945_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G et al (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19(9):589\u2013608","journal-title":"Nat Rev Drug Discov"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01945-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T13:10:21Z","timestamp":1727442621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01945-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01945-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no completing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}